Oxaprozin - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for oxaprozin and what is the scope of freedom to operate?
Oxaprozin
is the generic ingredient in four branded drugs marketed by Solubiomix, Pfizer, Abraxeolus, Actavis Elizabeth, Amneal Pharms Co, Beximco Pharms Usa, Chartwell, Dr Reddys Labs Ltd, Ivax Sub Teva Pharms, Mylan Pharms Inc, Norvium Bioscience, Sandoz, Sun Pharm Inds Inc, Teva, and Watson Labs, and is included in sixteen NDAs. Additional information is available in the individual branded drug profile pages.There are thirteen drug master file entries for oxaprozin. Eleven suppliers are listed for this compound.
Summary for oxaprozin
| US Patents: | 0 |
| Tradenames: | 4 |
| Applicants: | 15 |
| NDAs: | 16 |
| Drug Master File Entries: | 13 |
| Finished Product Suppliers / Packagers: | 11 |
| Raw Ingredient (Bulk) Api Vendors: | 117 |
| Clinical Trials: | 3 |
| Patent Applications: | 7,170 |
| Drug Prices: | Drug price trends for oxaprozin |
| What excipients (inactive ingredients) are in oxaprozin? | oxaprozin excipients list |
| DailyMed Link: | oxaprozin at DailyMed |
Recent Clinical Trials for oxaprozin
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Mochida Pharmaceutical Company, Ltd. | Phase 1 |
| Fuji Yakuhin Co., Ltd. | Phase 1 |
| Federal University of São Paulo | Phase 4 |
Pharmacology for oxaprozin
| Drug Class | Nonsteroidal Anti-inflammatory Drug |
| Mechanism of Action | Cyclooxygenase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for oxaprozin
US Patents and Regulatory Information for oxaprozin
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Norvium Bioscience | OXAPROZIN | oxaprozin | TABLET;ORAL | 075851-001 | Aug 17, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Actavis Elizabeth | OXAPROZIN | oxaprozin | TABLET;ORAL | 075843-001 | Oct 3, 2001 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pfizer | DAYPRO ALTA | oxaprozin potassium | TABLET;ORAL | 020776-001 | Oct 17, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Sun Pharm Inds Inc | OXAPROZIN | oxaprozin | TABLET;ORAL | 075844-001 | Jan 3, 2002 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
